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Abstract
Background: Preoperative lymphoscintigraphy is without doubt a valid method for the detection of the sentinel lymph
node (SLN). There has been considerable debate regarding the optimal site for the introduction of the tracer; various
sites include peritumoral (PT), periareolar (PA), subdermal, and intradermal injection.
Purpose: To evaluate retrospectively the lymphoscintigraphic identification rate of peritumoral (PT) injection versus
subdermal periareolar (PA) injection in the detection of SLNs in breast cancer.
Material and Methods: Between October 2002 and December 2011, a cohort of 906 consecutive patients with biopsy
proven breast cancer underwent 914 SLN biopsy procedures. A total of 339 procedures (Group A) were performed
using a PT deep injection of radiotracer while 575 procedures (Group B) adopted a subdermal PA injection of radio-
tracer towards the upper outer quadrant, regardless of the site of the carcinoma. All the patients underwent synchron-
ous excision of the breast cancer and SLN biopsy.
Results: SLNs were identified in the lymphoscintigram in 308/339 cases (90.85%) of Group A (PT injection) and in 537/
575 cases (93.39%) of Group B (PA injection). Furthermore, in 2/339 patients (0.58%) of Group A, internal mammary
lymph nodes were found at lymphoscintigraphy, whereas no internal mammary sentinel nodes were found in the Group B
patients. The intraoperative identification rate of axillary SLNs was 99.41% (337 of 339) in the Group A patients and
99.65% (573 of 575) in the Group B patients. There was no significant difference in the two groups between the
incidence of the number of SLNs detected and the incidence of identification of positive SLNs.
Conclusion: PT versus PA injection of radiotracer showed comparable success rates for axillary SLN identification, and
can be considered a rapid and reliable method.
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The sentinel lymph node biopsy (SLNB), was ﬁrst
introduced in the 1990s (1–3) and during recent years
has become more and more accepted as a method of
accurate axillary lymph node staging for breast cancer
(4–9). The sentinel lymph node (SLN) is deﬁned as the
ﬁrst lymph node in a regional basin that receives lymph
ﬂow from the primary tumor and it is thus the node
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with the highest probability of being involved in the
case of lymphatic spread from the tumor.
Today SLNB represents a minimally invasive opera-
tive procedure that can accurately predict the status of
axillary lymph nodes in clinical node-negative breast
cancer patients and represents an alternative to conven-
tional axillary lymph node dissection. The lymph drain-
age of the breast is relatively conﬁned to the axilla but
at times, though rarely, isolated lymphatic drainage of
internal mammary chain-SLNs is reported (2.6–4%),
and most surgeons therefore not always perform the
routine removal of extra-axillary nodes. (10,11).
When the SLNB technique was introduced for the
staging and treatment of breast cancer, preoperative
lymphoscintigraphy was introduced accordingly (1–
3,12,13). There has been some debate about the optimal
site for the introduction of the tracer. The various sites
of injection include peritumoral (PT), periareolar (PA),
subdermal, and intradermal injection (14,15). Despite
such a wide variety of modalities utilized for tracer
injection, the high rate of SLNs identiﬁcation and the
low incidence of false-negative cases are surprisingly
homogeneous (16). This observation has led to specu-
lations that the site of injection is relatively unimport-
ant, because the entire breast appears to drain to the
same SLN (17,18).
The aim of our study was to evaluate retrospectively
the lymphoscintigraphic identiﬁcation rate of diﬀerent
radio colloid injection techniques, comparing PT injec-
tion versus subdermal PA injection in the detection of
SLNs in breast cancer.
Material and Methods
A retrospective study was conducted on a cohort of 906
consecutive patients with biopsy proven breast cancer
that underwent 914 SLNB procedures between October
2002 and December 2011. Eight patients had bilateral
breast cancer. Patients with ductal carcinoma in situ
diagnosed at needle core biopsy and patients with
multifocal breast cancers were included in the study.
Patients with cytological positive lymph nodes, with
previous ipsilateral axillary surgery, and patients who
received neoadjuvant chemotherapy before surgery
were excluded from the study.
Lymphoscintigraphy
The lymphoscintigraphy injection protocol diﬀered in
the study period. From October 2002 to August 2006,
339 procedures (Group A) were performed using a PT
deep injection of radiotracer in the breast parenchyma
at four points. For non-palpable tumors the injection
was performed using ultrasound or stereotactic
guidance. From September 2006 to December 2011,
575 procedures (Group B) were performed using a sub-
dermal PA injection of radiotracer towards the upper
outer quadrant, regardless of the site of the carcinoma.
Lymphoscintigraphy was performed in the two
groups of patients at least 15, 30, and 180min after
the administration of 40–60 MBq 99mTc-labeled col-
loidal albumin in physiologic saline (Nanocoll, GE
Healthcare, Chicago, IL, USA). Images of the thoracic
region at anterior and oblique projections, including
the involved breast and axillary area, were acquired
using a digital gamma camera computer system with
a low-energy high-resolution collimator and an energy
peak at 140 KeV (General Electric Millennium MG
Gamma Camera Imaging System, Millennium GE,
Milwaukee, WI, USA). Only the ﬁrst hot spots outside
the injection site were identiﬁed as SLNs. Subsequently
a cobalt pen was used to locate the cutaneous projec-
tion of the SLN, and the skin overlying the hot spot
was marked with a skin marker.
Surgical procedure
All the patients underwent synchronous excision of the
breast cancer, either by conservative surgery or total
mastectomy, and SLN biopsy. In cases of non-palpable
breast lesions, a guidewire was placed in the tumor
site under either stereotactic or ultrasonographic
guidance.
For the intraoperative identiﬁcation of the SLN a
radio-guided surgical probe (Neoprobe neo2000
Gamma Detection Systems – Neoprobe Corporation,
Dublin, OH, USA) was used. In a very few cases, where
the radio-guided surgical probe picked up a weak radio-
tracer signal, about 10min before the beginning of sur-
gery a subdermal PA injection of 0.5–0.8mL of vital
stain (Lymphazurin 1%) was performed. All hot and/
or blue lymph nodes were removed.
All SLNs were examined at frozen section. SLNs
with a diameter <5mm were frozen intact, whereas
nodes with a diameter >5mm were bisected longitudin-
ally and frozen. Two 4 mm frozen sections were taken
from the optimal cross-sectional surface of one half of
the lymph node and stained with Hematoxylin and
Eosin (H&E) for intraoperative examination. For
deﬁnitive histopathological examination, all the
remaining tissue was formalin-ﬁxed and paraﬃn-
embedded.
All patients with SLN metastasis in frozen section
(FS) underwent immediate completion of total axillary
lymph nodes dissection (ALND). If the SLN was nega-
tive at FS but was found to contain metastasis in the
ﬁnal histopathology, patients underwent delayed com-
pletion of total ALND. No completion ALND was
performed in women with metastasis-free SLNs.
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Statistical methods
Chi-square test was performed to compare the rate
between the diﬀerent groups.
P< 0.05 was considered to be statistically
significant.
Results
The mean age of the patients was of 56.1 years (range,
35–81 years) in group A and of 54.7 years (range, 31–80
years) in group B. The features of the 914 tumors are
indicated in Table 1.
The average size of the tumors, evaluated on the
widest lesion, was 19.7 10.4mm (range, 4–53mm) in
group A and of 21.2 12.4mm (range, 6–57mm) in
group B.
The lymphoscintigram demonstrated SLNs in 308 of
the 339 cases (90.85%) of Group A (PT injection)
(Fig. 1) and in 537 of the 575 cases (93.39%) of
Group B (PA injection) (Fig. 2) (chi-square, 1.96;
P¼ 0.16)
Furthermore, in two of the 339 patients (0.58%) of
Group A, internal mammary lymph nodes were found
at lymphoscintigraphy, whereas no internal mammary
sentinel nodes were found in the Group B patients. No
diﬀerences in progression time of the radiotracer from
the injection site were observed between the two groups
of patients.
The intraoperative identiﬁcation rate of axillary
SLNs was 99.41% (337 of the 339 patients) in the
Group A patients. In 29 of the patients, pre-operative
lymphoscintigraphy did not identify the SLNs, which
were, however, identiﬁed intraoperatively. In the
Group B patients the intraoperative identiﬁcation rate
of axillary SLNs was 99.65 (573 of the 575 patients). In
Table 1. Features of the 914 tumors.
Group A Group B
Mean age (years) 56.1 (range,
35–81)
54.7 (range,
31–80)
Upper outer quadrant 188 55.6% 319 55.5%
Upper inner quadrant 64 18.9% 112 19.5%
Lower outer quadrant 47 13.9% 78 13.5%
Lower inner quadrant 31 9.1% 47 8.2%
Central 9 2.5% 19 3.3%
Bilateral breast cancer 3 0.88% 5 0.87%
pT1a 20 5.9% 38 6.6%
pT1b 76 22.4% 127 22.1%
pT1c 146 43.1% 246 42.8%
pT2 92 27.1% 155 26.9%
pT3 5 1.5% 9 1.6%
Invasive ductal 234 69.1% 403 70.1%
Invasive lobular 27 8.0% 51 8.9%
Invasive ductal
þ lobular
6 1.7% 11 1.9%
Other 58 17.1% 92 16.0%
Ductal carcinoma in situ 14 4.1% 18 3.1%
Fig. 2. Lymphoscintigraphy of the left breast: the large arrow
indicates the injection site of the radiotracer in the periareolar
region of the upper outer quadrant. After about 30min, the SLN
can be identified at the anterior pilaster of the axillary cavity
(small arrow).
Fig. 1. Lymphoscintigraphy of the right breast: the large arrow
indicates the injection site of the radiotracer within the tumor
site. It can be seen that the radiotracer also tends to spread in
the peritumoral area with the typical ‘‘drop’’ morphology. The
small arrow indicates the SLN.
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36 of the 38 patients, preoperative lymphoscintigraphy
did not identify the SLNs, which were, however, iden-
tiﬁed intraoperatively.
In four cases of failure to ﬁnd the SLN, axillary
lymphadenectomy was performed in any case on
principle.
The average number of detected SLNs was
1.88 0.9 in group A and 1.91 0.7 in group B. The
number of metastatic SLNs was 69 (20.3%) in group A
and 114 (19.8%) in group B. The average number of
detected SLNs and the incidence of positive SLNs were
not signiﬁcantly diﬀerent between the groups of
patients (chi-square 0.29; P¼ 0.59).
Discussion
Various sites of injection including the PT, subdermal,
intradermal, and PA have been described, but the opti-
mal site of tracer injection has long been a matter of
debate.
The ﬁrst technique used in SLB was PT and this has
become common in a clinical setting. Nevertheless,
there are some diﬃculties involved by this method, par-
ticularly regarding the operator’s experience in making
the correct radiotracer injection, and also in the case of
non-palpable tumors, where ultrasound or stereotactic
guidance is required.
There are also other problems related to the fact that
it is necessary to perform several injections in the peri-
tumoral site, since the lymphatic structures, depending
on their depth, may be represented in varying degrees,
and may also be inﬁltrated by the tumor with reduced
progression of the tracer, which will tend to accumulate
at the injection site. For these reasons this approach has
been criticized especially in non-palpable and multi-
centric tumors and in those lesions located in the
upper outer quadrant because of the shine-through
phenomenon determining high background noise in
the axilla.
Subdermal PA injection of the radiotracer, more
recently introduced, is a simple and easy method that
does not require extensive experience (19). Several stu-
dies have emphasized the importance of the subareolar
lymphatic plexus on the basis of the high number of
lymphatic tracts in this area compared with those in the
breast parenchyma.
This ﬁnding may be explained by the embryologic
development of the breast from the epithelium of the
primitive milk streak. During development, lymphatic
vessels elongate and grow synchronously in parallel
with the growth of the lactiferous ducts, but they stay
connected with the subareolar plexus. The subareolar
plexus communicates with superﬁcial and deep intra-
mammary channels and drains into the regional
lymph nodes via one or two large lymph trunks.
These channels maintain their connection to the SA
lymphatic plexus in the mature breast.
The hypothesis of the existence of a common plexus
between deep and periareolar lymphatic vessels has
been conﬁrmed by several other authors (20,21).
In our retrospective study, we compared the lymph-
atic ﬂow in the breast using the two injection sites PT
and subdermal PA in two series of patients. In accord-
ance with other authors, the results obtained conﬁrm
that the entire breast, including the nipple-areola com-
plex, drains into the same axillary lymph nodes (22–24).
With subdermal PA injection a higher number of SLNs
is identiﬁed (1.88 0.9 vs. 1.91 0.7) but it is most
important to identify the node that is the ﬁrst draining
step of the tumor tissue, and lymphoscintigraphy is able
to identify it with accuracy. In our experience, the rate
of positive nodes is not signiﬁcantly diﬀerent in the two
groups of patients.
Several authors state that PA injections detect fewer
extra-axillary nodes than the PT injection (10,11).
Borgstein et al. have also admitted that the only possible
disadvantage of the PA injection lies in its inability to
permit detection of accessory lymphatic pathways, espe-
cially with regard to the internal mammary chain (21).
Our experience conﬁrms this and, in fact, with the
PA injection we did not ﬁnd any nodes outside the axil-
lary site, compared with the PT injection, where we
found 4/796 internal mammary chain nodes (0.5%).
Nevertheless, it must also be born in mind that most
surgeons do not remove extra-axillary nodes routinely.
However, the treatment of internal mammary chain
nodes is a matter of debate; some authors aﬃrm that
dissection of the internal mammary chain lymph nodes
beneﬁts only a small portion of breast cancer patients,
and would result in more injures to these patients and
lead to more complications (25–27). Several other
authors are of a completely diﬀerent opinion, stating
that the therapy was altered in a substantial proportion
of patients by internal mammary SLNB and survival
was worse in patients who had internal mammary
drainage that was not taken into account when adju-
vant therapy was planned (28,29).
In our opinion, there are not enough published
works on the subject, and more large clinical trials
are necessary in order to explore the value of internal
mammary node biopsy.
Finally, a slight improvement in the sensitivity of
lymphoscintigraphy occurred in Group B patients com-
pared with the Group A (90.85 vs. 93.39); in our opin-
ion, this was due to the optimization of the technique
by the medical staﬀ concerned.
The results obtained conﬁrm the hypothesis that the
lymphatic pathways draining diﬀerent areas of the
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breast parenchyma, and the subareolar plexus leads to
the same sentinel lymph node. PT versus PA injection of
radiotracer showed comparable success rates for axil-
lary SLNs identiﬁcation. PA injection of radiotracer
showed comparable success rates for axillary SLNs
identiﬁcation.
In conclusion, we believe that the PA injection is to
be considered the method of choice in the identiﬁcation
of SLNs. In fact, it can be considered a rapid and reli-
able method, with a low radiation dose for the patients
that does not require either extensive experience on the
part of the operator and or the use of ultrasound or
stereotactic guidance in peritumoral injection for iden-
tifying SLNs in breast cancer patients. It is easy to per-
form, especially in non-palpable breast cancer.
Funding
This research received no speciﬁc grant from any funding
agency in the public, commercial, or not-for-proﬁt sectors.
References
1. Giuliano AE, Kirgan DM, Guenther JM, et al.
Lymphatic mapping and sentinel lymphadenectomy for
breast cancer. Ann Surg 1994;220:391–398.
2. Morton DL, Wen DR, Wong JH, et al. Technical details
of intraoperative lymphatic mapping for early stage mel-
anoma. Arch Surg 1992;127:392–399.
3. Van der Veen H, Hoekstra OS, Paul MA, et al. Gamma
probe-guided sentinel node biopsy to select patients with
melanoma for lymphadenectomy. Br J Surg
1994;81:1769–1770.
4. Ciafrocca M, Goldstein LJ. Prognostic and predictive
factors on early-stage breast cancer. Oncologist
2004;9:606.
5. Banerjee M, George J, Song EY, et al. Tree-based model
for breast cancer prognostication. J Clin Oncol
2004;22:2567–2575.
6. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph
node biopsy and axillary dissection in breast cancer:
results in a large series. J Natl Cancer Inst
1999;91:368–373.
7. Posther KE, Wilke LG, Giuliano AE. Sentinel lymph
node dissection and the current status of American
trials on breast lymphatic mapping. Semin Oncol
2004;31:426–436.
8. Wang Y, Yu J, Wang L. The study of sentinel node
biopsy in clinical node negative breast cancer in China.
Breast Cancer Res Treat 2004;88:S89.
9. McMasters KM, Giuliano AE, Ross MI, et al. Sentinel-
lymph-node biopsy for breast cancer-not yet the standard
of care. N Engl J Med 1998;339:990–995.
10. van der Ploeg I, Tanis PJ, Valdes Olmos RA, et al. Breast
cancer patients with extra-axillary sentinel nodes only
may be spared axillary lymph node dissection. Ann
Surg Oncol 2008;15:3239–3243.
11. Estourgie SH, Nieweg OE, Olmos RA, et al. Lymphatic
drainage patterns from the breast. Ann Surg
2004;239:232–237.
12. Anagnostou C, Baiocco C, Arnulfo A, et al. The value of
imaging in standing position in preoperative breast lym-
phoscintigraphy. Clin Nucl Med 2011;36:683–688.
13. Leidenius MH. Sentinel node biopsy in breast cancer.
Acta Radiol 2005;46:791–801.
14. Rodier JF, Velten M, Wilt M, et al. Prospective multi-
centric randomized study comparing periareolar and
peritumoral injection of radiotracer and blue dye for
the detection of sentinel lymph node in breast sparing
procedures: FRANSENODE trial. J Clin Oncol
2007;20:3664–3669.
15. Shimazu K, Tamaki Y, Uchi T, et al. Comparison
between periareolar and peritumoral injection of radio-
tracer for sentinel lymph node biopsy in patients with
breast cancer. Surgery 2002;131:277–286.
16. Sandrucci S, Sorba Casalegno P, Percivale P, et al.
Sentinel lymph node mapping and biopsy for breast
cancer: a review of the literature relative to 4791 proced-
ures. Tumori 1999;85:425–434.
17. Kern KA. Sentinel lymph node mapping in breast cancer
using subareolar injection of blue dye. J Am Coll Surg
1999;189:539–545.
18. Smith LF, Cross MJ, Klimberg VS. Subareolar injection
is a better technique for sentinel lymph node biopsy. Am
J Surg 2000;180:434–438.
19. Leikola JP, Leppa¨nen EA, von Smitten KA, et al. A
second radioisotope injection enhances intraoperative
sentinel node identification in breast cancer patients with-
out visualized nodes on preoperative lymphoscintigraphy.
Acta Radiol 2006;47:760–763.
20. Tanis PJ, Nieweg OE, Olmos RA, et al. Anatomy and
physiology of lymphatic drainage of the breast from the
perspective of sentinel node biopsy. J Am Coll Surg
2001;192:399–404.
21. Borgstein PJ, Meijer S, Pijpers RJ, et al. Functional
lymphatic anatomy for sentinel node biopsy in breast
cancer: echoes from the past and the periareolar blue
method. Ann. Surg 2000;232:81–89.
22. Kargozaran H, Shah M, Li Y, et al. Concordance of
peritumoral technetium 99m colloid and subareolar blue
dye injection in breast cancer sentinel lymph node biopsy.
J Surg Res 2007;143:126–129.
23. Garcia-Manero M, Olartecoechea B, Royo P.
Different injection sites of radionuclide for sentinel
lymph node detection in breast cancer: single institution
experience. Eur J Obstet Gynecol Reprod Biol
2010;153:185–187.
24. Bauer TW, Spitz FR, Callans LS, et al. Subareolar and
peritumoral injection identify similar sentinel nodes for
breast cancer. Ann Surg Oncol 2002;9:169–176.
25. Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, et al.
Comprehensive review of the management of internal
mammary lymph node metastases in breast cancer. J
Am Coll Surg 2001;193:547–555.
26. Chen RC, Lin NU, Golshan M, et al. Internal mammary
nodes in breast cancer: diagnosis and implications for
Caruso et al. 43
patient management - a systematic review. J Clin Oncol
2008;26:4981–4989.
27. Domenech-Vilardell A, Bajen MT, Benitez AM, et al.
Removal of the internal mammary sentinel node in
breast cancer. Nucl Med Commun 2009;30:962–970.
28. Paredes P, Vidal-Sicart S, Zanon G, et al. Clinical rele-
vance of sentinel lymph nodes in the internal mammary
chain in breast cancer patients. Eur J Nucl Med Mol
Imaging 2005;32:1283–1287.
29. Madsen E, Gobardhan P, Bongers V, et al. The impact
on post surgical treatment of sentinel lymph node biopsy
of internal mammary lymph nodes in patients with breast
cancer. Ann Surg Oncol 2007;14:1486–1492.
44 Acta Radiologica 55(1)
Copyright of Acta Radiologica is the property of Sage Publications, Ltd. and its content may
not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's
express written permission. However, users may print, download, or email articles for
individual use.
